| MTX-LPD | ML | p value |
| n = 11 | n = 21 |
|
Mean age (y) | 68.5 (57 - 75) | 60.6 (13 - 82) | 0.21 |
Gender (female:male) | 9:2 | 7:14 | 0.02 |
Mean period from the introduction of MTX (mo) | 60.0 (18 - 125) | - | - |
Mean dose of MTX at the diagnosis (mg/week) | 8.38 (6 - 15) | - | - |
Mean sIL-2R value (U/ml) | 2607 (475 - 12653) | 1362 (217 - 6887) | 0.20 |
Mean value of lactate dehydrogenase (IU/I/37˚C) | 267.3 (176 - 449) | 303.0 (152 - 1128) | 0.66 |
Pathology |
|
| 1.0 |
DLBCL | 6 (54.5%) | 12 (57.1%) |
|
Hodgkin | 3 (27.3%) | 5 (23.8%) |
|
MALT | 1 (9.1%) | 2 (9.5%) |
|
PTCL | 1 (9.1%) | 2 (9.5%) |
|
Mean blood glucose at PET scan (mg/dl) | 85.9 (71 - 99) | 89.4 (62 - 177) | 0.64 |
Mean SUVmax | 14.6 (3.6 - 32.8) | 17.2 (5.3 - 39.5) | 0.49 |
Presence of nodal lesion (n) | 8 (72.7%) | 20 (95.2%) | 0.11 |
Presence of extranodal lesion (n) | 11 (100%) | 7 (33.3%) | <0.001 |